Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

Glioblastoma Multiforme Clinical Trial

Official title:

Phase I, Open-label, Multicenter Study to Evaluate the Imaging Performance, Safety, Biodistribution and Dosimetry of [68Ga]-FF58 in Adult Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04712721
• Other study ID #: CAAA504A12101
• Secondary ID: 2020-004038-39
• Status: Recruiting
• Phase: Early Phase 1
• Start date: October 14, 2021
• Est. completion date: June 5, 2024

Study information

• Verified date: April 2024
• Source: Novartis
• Contact: Novartis Pharmaceuticals
• Phone: 1-888-669-6682
• Email: novartis.email[@]novartis.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a First-In-Human (FIH) study of [68Ga]-FF58 to characterize the imaging properties, safety, biodistribution and dosimetry properties of [68Ga]-FF58 in adults with relapsed or refractory (r/r) glioblastoma multiforme (GBM), breast cancer (BC) that has metastasized to the brain, gastroesophageal adenocarcinoma (GEA) or pancreatic ductal adenocarcinoma (PDAC) expected to overexpress alpha-v beta 3 (αvβ3) and alpha-v beta 5 (αvβ5) integrins.

Description:

Approximately 80 patients will be enrolled into the study, 20 patients with GBM, 20 patients with BC that has metastasized to the brain, 20 with GEA and 20 with PDAC. The study will have an imaging characterization part and an expansion part. In the imaging characterization part, approximately 24 patients will be enrolled, 6 with r/r GBM, 6 with BC that has metastasized to the brain, 6 with GEA and 6 with PDAC. Both parts of the study (imaging characterization and expansion) will include a dosimetry sub-group in which the distribution, pharmacokinetics (PK), radiation dosimetry and absorbed doses in tissue and tumor will be assessed. All patients enrolled in the study will receive a single dose of [68Ga]-FF58 and undergo [68Ga]-FF58 PET imaging at different timepoints on Day 1 as well as conventional imaging (high resolution CT or MRI). The estimated study duration for each individual patient is approximately 44 days (including screening period of 28 days and 14 days of follow-up (FU)).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: June 5, 2024
• Est. primary completion date: June 5, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed informed consent must be obtained prior to participation in the study
• Patients with histologically or cytologically confirmed and documented r/r GBM that has progressed after prior radiation therapy and have not received prior bevacizumab OR patients with BC that has metastasized to the brain and who should have at least one newly diagnosed brain metastasis that has not been resected or irradiated, or has been irradiated and progressed OR patients with histologically or cytologically confirmed and documented locally advanced or metastatic GEA (i.e., adenocarcinoma of the stomach (intestinal subtype), esophagus, or gastroesophageal junction), either untreated or r/r after one or more lines of treatment OR patients with histologically or cytologically confirmed and documented locally advanced or metastatic PDAC, either untreated or r/r after one or more lines of treatment.

Exclusion Criteria:

• Creatinine clearance (calculated using Cockcroft-Gault formula) <40 mL/min.
• Unmanageable bladder outflow obstruction or urinary incontinence.
• QTcF > 480 msec on screening ECG or congenital long QT syndrome.
• Any condition that requires chronic treatment with anticoagulants or antiplatelet agents
• Patients with a known bleeding disorder
• Administration of a radiopharmaceutical within a period corresponding to 10 half-lives of the radionuclide used prior to injection of [68Ga]-FF58.
• Pregnant women. Women who are breastfeeding must express and discard breast milk for 12 hours after [68Ga]-FF58 administration and must also stop breast feeding during this same period. Males and females must abstain from sexual intercourse for 12 hours after [68Ga]-FF58 administration.
• Total bilirubin > 1.5 x ULN (except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 x ULN) or direct bilirubin > 1.5 x ULN
• Alanine aminotransferase (ALT) > 3 x ULN, except for patients that have tumor involvement of the liver, who are excluded if ALT > 5 x ULN
• Aspartate aminotransferase (AST) > 3 x ULN, except for patients that have tumor involvement of the liver, who are excluded if AST > 5 x ULN

Related Conditions & MeSH terms

• Adenocarcinoma
• Brain Neoplasms
• Gastroesophageal Adenocarcinoma
• Glioblastoma
• Glioblastoma Multiforme
• Pancreatic Ductal Adenocarcinoma

Intervention

Drug:
• 68Ga-FF58
Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.

Locations

Country	Name	City	State
France	Novartis Investigative Site	Lyon
Germany	Novartis Investigative Site	Essen
United States	City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr1	Duarte	California
United States	Uni of TX MD Anderson Cancer Cntr	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  France,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Non-decay corrected tissue time-activity curves (TACs) from 68Ga-FF58 PET/CT images	Time activity curves (TACs) for the various organs will be produced as non decay-corrected fraction of injected activity (%IA) per organ.	[68Ga]-FF58 PET imaging acquired at Day 1
Primary	Number of lesions detected by [68Ga]-FF58	The preliminary targeting properties of [68Ga]-FF58 will be assessed by summarizing the number of lesions identified by Positron Emission Tomography (PET), as well as by tumor type.	[68Ga]-FF58 PET imaging acquired at Day 1
Primary	Number of Participants with Lesions detected by [68Ga]-FF58 per Location	The preliminary targeting properties of [68Ga]-FF58 will be assessed by summarizing the location of lesions identified by PET, as well as by tumor type.	[68Ga]-FF58 PET imaging acquired at Day 1
Primary	Standard Uptake Value (SUV) mean and max in lesions detected by PET scans	Targeting properties of 68GaFF58 will be evaluated by semi quantitatively assessing radiotracer uptake at lesion level, identified via PET/CT imaging (4 scans). The SUVmean and SUVmax of each lesion will be calculated and reported by lesion location with summary statistics.	[68Ga]-FF58 PET imaging acquired at Day 1
Primary	Tumor to Background Ratio (TBR) of lesions detected by PET scans	Targeting properties of 68Ga-FF58 will be evaluated by semi quantitatively assessing radiotracer uptake at lesion level, identified via PET/CT imaging (4 scans). The lesion Tumor to Background Ratio (TBR) will be defined as the ratio of the lesion SUV over the reference region SUV. TBRs will be calculated for both SUVmax(lesion) / SUVmean and reported by lesion location with summary statistics. Different regions will be used as reference, in order to satisfy the most appropriate one for each type of lesion.	[68Ga]-FF58 PET imaging acquired at Day 1
Secondary	Number of Participants with Treatment Emergent Adverse Events	Treatment-emergent adverse events (TEAEs) will be collected from first dosing (single administration, Day 1) up to last follow-up visit or the patient withdrew consent. The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.	From first dosing (single administration, Day 1) up to 14 days post infusion
Secondary	Percentage of lesions detected by conventional scans, PET scans, or both modalities	The percentage of lesions detected by conventional imaging (high resolution CT or MRI acquired jointly or within 24 hours before or after the [68Ga]-FF58 PET scan), [68Ga]-FF58 PET scans , or both modalities will be summarized descriptively for all patients and split by indication.	[68Ga]-FF58 PET imaging acquired at Day 1
Secondary	Lesion-level analyses of diagnostics by [68Ga]-FF58 compared with conventional imaging	At lesion level, overall, positive, and negative agreement of [68Ga]-FF58 will be calculated based on the aforementioned tabulations as follows: • Overall agreement = 100% x (Double positive + Double negative) / total number of lesions identified by either imaging procedures; Positive agreement = 100% x Double positive / (Double positive + Comparator single positive); Negative agreement = 100% x Double negative / (Double negative + Comparator single negative).	[68Ga]-FF58 PET imaging acquired at Day 1
Secondary	Dosimetry Group: Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of 68Ga-FF58	Venous whole blood samples will be collected and analysed for radioactivity. Radioactivity-based concentration units will be converted to mass-based concentration units using the specific activity of the dose at the time of manufacture (MBq/µg). Pharmacokinetics characterization will be performed on mass-based concentrations. AUClast will be listed and summarized using descriptive statistics.	Day 1 (0, 0-5, 10, 30, 60, 120, 180-240, 300 minutes post infusion)
Secondary	Dosimetry Group: Time of maximum observed drug concentration occurrence (Tmax) of 68Ga-FF58	Venous whole blood samples will be collected and analysed for radioactivity. Radioactivity based concentration units will be converted to mass-based concentration units using the specific activity of the dose at the time of manufacture (MBq/µg). Pharmacokinetics characterization will be performed on mass-based concentrations. Tmax will be listed and summarized using descriptive statistics.	Day 1 (0, 0-5, 10, 30, 60, 120, 180-240, 300 minutes post infusion)
Secondary	Dosimetry Group: Observed maximum plasma concentration (Cmax) of 68Ga-FF58	Venous whole blood samples will be collected and analysed for radioactivity. Radioactivity based concentration units will be converted to mass-based concentration units using the specific activity of the dose at the time of manufacture (MBq/µg). Pharmacokinetics characterization will be performed on mass-based concentrations. Cmax will be listed and summarized using descriptive statistics.	Day 1 (0, 0-5, 10, 30, 60, 120, 180-240, 300 minutes post infusion)
Secondary	Dosimetry Group: Terminal elimination half-life (T^1/2) of 68Ga-FF58	Venous whole blood samples will be collected and analysed for radioactivity. Radioactivity based concentration units will be converted to mass-based concentration units using the specific activity of the dose at the time of manufacture (MBq/µg). Pharmacokinetics characterization will be performed on mass-based concentrations. The half-life will be listed and summarized using descriptive statistics.	Day 1 (0, 0-5, 10, 30, 60, 120, 180-240, 300 minutes post infusion)
Secondary	Dosimetry Group: Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of 68Ga-FF58	Venous whole blood samples will be collected and analysed for radioactivity. Radioactivity based concentration units will be converted to mass-based concentration units using the specific activity of the dose at the time of manufacture (MBq/µg). Pharmacokinetics characterization will be performed on mass-based concentrations. AUCinf will be listed and summarized using descriptive statistics.	Day 1 (0, 0-5, 10, 30, 60, 120, 180-240, 300 minutes post infusion)
Secondary	Dosimetry Group: Total systemic clearance for intravenous administration (CL) of 68Ga-FF58	Venous whole blood samples will be collected and analysed for radioactivity. Radioactivity based concentration units will be converted to mass-based concentration units using the specific activity of the dose at the time of manufacture (MBq/µg). Pharmacokinetics characterization will be performed on mass-based concentrations. CL will be listed and summarized using descriptive statistics.	Day 1 (0, 0-5, 10, 30, 60, 120, 180-240, 300 minutes post infusion)
Secondary	Dosimetry Group: Volume of distribution during the terminal phase following intravenous elimination (Vz) of 68Ga-FF58	Venous whole blood samples will be collected and analysed for radioactivity. Radioactivity based concentration units will be converted to mass-based concentration units using the specific activity of the dose at the time of manufacture (MBq/µg). Pharmacokinetics characterization will be performed on mass-based concentrations. Vz will be listed and summarized using descriptive statistics.	Day 1 (0, 0-5, 10, 30, 60, 120, 180-240, 300 minutes post infusion)
Secondary	Dosimetry Group: Urinary excretion of radioactivity expressed as a percentage of injected activity (%IA)	Urine samples will be collected over specified time intervals and analysed for radioactivity. The radioactivity excreted in each interval as a percentage of injected activity (%IA) will be listed and summarized using descriptive statistics.	Day 1 (0-30, 30-120, 120-180, 180-300 minutes post infusion)
Secondary	Dosimetry Group: Absorbed dose of 68Ga- FF58	The absorbed dose in target organs will be summarized with descriptive statistics. Lesion number will be assigned by dosimetry expert.	[68Ga]-FF58 PET imaging acquired at Day 1
Secondary	Dosimetry Group: Effective whole-body dose of 68Ga- FF58	The effective radiation dose will be summarized with descriptive statistics. Lesion number will be assigned by dosimetry expert.	[68Ga]-FF58 PET imaging acquired at Day 1